Drug Profile

Tetracosactide - Cerium Pharmaceuticals

Alternative Names: Tetracosactide hexaacetate - Cerium Pharmaceuticals

Latest Information Update: 28 Nov 2019

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cerium Pharmaceuticals
Class Anti-inflammatories; Antidepressants; Corticosteroids; Diagnostic agents; Immunotherapies; Melanocortins; Peptides
Mechanism of Action Melanocortin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Infantile spasms
New Molecular Entity No

Highest Development Phases

Discontinued Infantile spasms

Most Recent Events

28 Nov 2019 Discontinued - Preclinical for Infantile spasms in USA (unspecified route) (Cerium Pharmaceuticals website, November 2019)
21 Nov 2019 No development reported - Preclinical for Infantile spasms in USA (unspecified route) (Cerium Pharmaceuticals website, November 2019)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com